Regolamentazione e diritto · 30/09/20081 min di lettura
Prospective Grant of an Exclusive License: Therapeutics Based on Histone Deacetylase (HDAC) Inhibitors for the Prevention and Treatment of Central Nervous System (CNS) Metastases of Extra-CNS Origin Cancers
Traduzione automatica locale · Lingua originale della fonte
Riepilogo
This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), announces that the Department of Health and Human Services is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Provisional Application 60/891,856 filed February 27, 2007 (E-084-2007/0-US-01) and International Application PCT/US2008/055149 filed February 27, 2008 (E-084-2007/0- PCT-02), entitled "Use of Histone Deacetylase Inhibitors for the Treatment of Central Nervous System Metastases," to Waypharm S.A.S. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be the United States and Europe, and the field of use may be limited to therapeutics based on CNS metastases of extra-CNS origin cancers.